Repositorio Dspace

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

Mostrar el registro sencillo del ítem

dc.creator Salerno, Francesco
dc.creator Gerbes, Alexander L.
dc.creator Ginès i Gibert, Pere
dc.creator Wong, Florence
dc.creator Arroyo, Vicente
dc.date 2011-07-07T11:32:55Z
dc.date 2011-07-07T11:32:55Z
dc.date 2007
dc.date.accessioned 2024-12-16T10:27:13Z
dc.date.available 2024-12-16T10:27:13Z
dc.identifier 0017-5749
dc.identifier http://hdl.handle.net/2445/18628
dc.identifier 557500
dc.identifier 17389705
dc.identifier.uri http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/22085
dc.description Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its functional nature, HRS is associated with a poor prognosis,3 4 and the only effective treatment is liver transplantation. During the 56th Meeting of the American Association for the Study of Liver Diseases, the International Ascites Club held a Focused Study Group (FSG) on HRS for the purpose of reporting the results of an international workshop and to reach a consensus on a new definition, criteria for diagnosis and recommendations on HRS treatment. A similar workshop was held in Chicago in 1994 in which standardised nomenclature and diagnostic criteria for refractory ascites and HRS were established.5 The introduction of innovative treatments and improvements in our understanding of the pathogenesis of HRS during the previous decade led to an increasing need to undertake a new consensus meeting. This paper reports the scientific rationale behind the new definitions and recommendations. The international workshop included four issues debated by four panels of experts (see Acknowledgements). The issues were: (1) evidence-based HRS pathogenesis; (2) treatment of HRS using vasoconstrictors; (3) other HRS treatments using transjugular intrahepatic portosystemic stent-shunt (TIPS) and extracorporeal albumin dialysis (ECAD); and (4) new definitions and diagnostic criteria for HRS and recommendations for its treatment.
dc.format 9 p.
dc.format application/pdf
dc.language eng
dc.publisher BMJ Group
dc.relation Reproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.2006.107789
dc.relation Gut, 2007, vol. 56, núm. 9, p. 1310-1318
dc.relation http://dx.doi.org/10.1136/gut.2006.107789
dc.rights (c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 2007
dc.rights info:eu-repo/semantics/openAccess
dc.source Articles publicats en revistes (Medicina)
dc.subject Cirrosi hepàtica
dc.subject Malalties del ronyó
dc.subject Diagnòstic
dc.subject Medicina preventiva
dc.subject Terapèutica
dc.subject Hepatic cirrhosis
dc.subject Kidney diseases
dc.subject Diagnosis
dc.subject Preventive medicine
dc.subject Therapeutics
dc.title Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
dc.type info:eu-repo/semantics/article
dc.type info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta